Navigation Links
A study led by CNIO validates a new anti-cancer therapy based on cell division
Date:11/18/2013

Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on adult tissues are still unknown.

A study led by Ignacio Pérez de Castro, a researcher in the Spanish National Cancer Research Centre's (CNIO) Cell Division and Cancer Group, and its Group Leader, Marcos Malumbres, describes the cellular consequences of genetically deleting Aurora-A, an important target for the development of new anti-cancer agents, in mouse models. The work, which was carried out in collaboration with researchers Terry Van Dyke and Dale Cowley, from North Carolina University in the US, is published today in Cancer Research, the most cited cancer journal.

AURORA-A, AGEING AND CANCER

Aurora-A is a protein involved in the regulation of the cell cycle, a process by which cells reproduce and form tissues. Although these elementary functions had been widely studied in several model organisms and mouse embryos, their role in tissues and adult organisms remained unknown.

Using genetically engineered Aurora-A deficient mice, the authors of the study have discovered that the absence of this protein causes an increase in the number of cells with a high DNA content; this is a consequence of an aberrant distribution of the genetic material upon division.

"This phenomenon causes defects in cell proliferation, as well as an increase in the number of dead and senescent cells, which triggers premature ageing in the animals studied", says Ignacio Pérez de Castro. The researcher adds that: "In those mice, we also see an increase in DNA damage and, most importantly, a reduction in the progression of skin and breast tumours".

The study helps to solve two of the great limitations pharmaceutical companies find themselves up against when they carry out clinical trials with Aurora protein inhibitors. Firstly, the compounds used in clinical trials are not completely specific and are not capable of adequately discriminating between the three members of the Aurora family: Aurora- A, B or C. Mice generated by CNIO confirm the therapeutic value of the first member of this family of proteins.

"Secondly, clinical studies with these inhibitors have surveillance problems as a result of the lack of markers that allow monitoring their effects on the cells", says Marcos Malumbres. The researchers propose studying the volume of the cell nucleus, a consequence of a change in DNA content, as a new tool for evaluating the efficiency of these new anti-cancer drugs.

Given that Aurora-A inhibition damages DNA, Malumbres's team says that the use of Aurora-A inhibiting drugs could sensitise tumours to anti-cancer agents that are currently in clinical use and attack cells causing high levels of DNA damage.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Influence of pro-smoking media messages lasts 7 days, study finds
2. Study compares outcomes of device for chest compressions vs manual CPR
3. Study examines effectiveness, safety of transcatheter aortic valve replacement in US
4. New Study Reports on the High Cost of Cardiac Surgery Healthcare Associated Infections
5. Narconon Arrowhead Provides Bible Study Classes
6. Study Highlights Challenges for Individuals with Lung Cancer, Allsup Reports
7. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
8. Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
9. Multicenter study underscored the need of a uniform approach to the treatment of BCa
10. Regenstrief and IU study: Older adults with severe mental illness challenge healthcare system
11. Workers’ Compensation Costs Per Claim Moderating In Pennsylvania After Years of Growth, New Study Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... The ... Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for member ... effort through Guild collaborative teams. , Non-members may download the Part 1 ...
(Date:7/20/2017)... ... July 20, 2017 , ... LINET, an international leader in healthcare ... product line: the AVE 2 birthing bed. , Perfectly suitable for labor, delivery, recovery ... of comfort and efficiency to every phase of childbirth. The AVE 2 has many ...
(Date:7/20/2017)... ... July 19, 2017 , ... At Creekwood Dental Arts, Drs. Donna G. ... treatment and dental implants in Waco, TX, using the latest dental technology ... by Tekscan®, they can capture details in the oral cavity for accurate diagnoses and ...
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson ... healthcare project manager, Josh Christensen. As a leader in healthcare construction, AP has ... its healthcare resume in the Midwest with Josh now on board. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed memoir ... public high school music and drama teacher who was a summa cum laude graduate ... a “Teacher of the Year” award. After her retirement from public school, Lynn continued ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Analytical, a company of over 2,000 employees and a leader in environmental and ... further solidifying their position as the top American owned and operated environmental testing ... ... ... Juliet, TN , enhances Pace Analytical,s capability as an innovative full service ...
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)... (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia ... AVACEN Treatment Method to significantly reduce the widespread pain symptom ... ... ... to 400 million people worldwide according to The National Fibromyalgia Association. ...
Breaking Medicine Technology: